The adoption of environmental, social, and governance (ESG) strategies presents opportunities for sustainable and inclusive growth. Incorporating ESG strategies not only enhances societal, and environmental impact but also ensures long-term competitiveness. Our approach to ESG amalgamates our deep understanding of the factors driving value and impact within specific sectors.
ESG priorities have emerged as key drivers of long-term success, pushing all companies, including in the pharma sector, to adopt sustainable practices and foster social responsibility. In this blog, we explore the critical importance of ESG priorities and diversity and inclusion for the pharmaceutical sector.
Nurturing a greener future through Environmental Responsibility
ESG-driven companies are adopting a broad perspective of environmental responsibility, moving away from waste management alone and adopting a holistic view. Companies are now dedicated to making a substantial positive contribution to the environment. This is achieved through strategic collaborations and support for diverse projects aimed at diminishing carbon emissions, fostering environmental sustainability, and advancing reforestation endeavors. Emphasizing the reduction of air pollution, backing efforts to clean lakes and beaches, and providing funds for projects that enhance urban tree coverage, all underline a strong dedication to protecting the environment and conserving natural resources for the future generations.
Supporting the needs of the community to mark Social Responsibility
Life Sciences, pharma and clinical research companies have for a long time focused on improving the lives of patients in need. However, the focus on social responsibility goes beyond drug development and extends to equitable access to healthcare, community engagement, and employee well-being. Social initiatives to improve healthcare access in underserved regions demonstrate a commitment to their broader societal impact. Such efforts foster a sense of purpose among employees and help build a socially responsible community.
Empowering Corporate Governance
Effective corporate governance ensures ethical decision-making, risk management, and transparency. By prioritizing these aspects, there is mitigation of risk and improved productivity. A diverse team plays a significant role in advancing business outcomes, improving corporate governance, strengthening the capacity for quality and responsible decision-making, fostering sustainable development, and elevating the company's reputation.
Diversity & Inclusion to Foster Improved Representation and Innovation
Diversity and inclusion (D&I) are pivotal for infusing innovation and problem-solving. Inclusive workplaces attract and retain top talent, creating a more equal and value creation. D&I initiatives extend beyond internal practices in a clinical research organization (CRO), influencing patient population and marketing strategies that are meaningful and impact diverse beneficiaries.
Why are diverse participants important in clinical trials?
We need to be able to include a diverse population when we are conducting clinical trials. This will help us understand drug response(s) across different ethnic groups. A lot of minority groups, especially in the U.S, don’t get the right medical care, and one way of ensuring that is to include them in clinical trials.
Sr. Clinical research Associate,
Navitas Clinical Research
Vendor Diversification: Safeguarding Supply Chains
A vendor or supplier diversity is when an individual or a group of people belonging to an under-represented community own at least 51% stake in the enterprise. This could include businesses that are owned by women, minority communities etc. This not only raises moral and ethical standards but also brings in increased revenue for the under-represented communities.
Moreover, sourcing from multiple suppliers, lowers the risk of supply chain disruptions due to external factors like natural disasters, or economic fluctuations. By being inclusive, pharmaceutical companies ensure stable partnerships, contributing to the industry's resilience.
A focus on ESG and diversity & inclusion, including vendor diversification, efforts are imperative to contributing towards a healthier, more equitable, and sustainable future.
Read more about diversity and inclusion here.
Navitas Life Sciences’ Patient Population Contribute towards Diversity for a Global Study
Read more about our end-to-end clinical trials here.
To find out more about our services and solutions, reach out to us at